Pharmaceutics (Mar 2023)

Self-Assembled Lecithin-Chitosan Nanoparticles Improved Rotigotine Nose-to-Brain Delivery and Brain Targeting Efficiency

  • Paramita Saha,
  • Prabhjeet Singh,
  • Himanshu Kathuria,
  • Deepak Chitkara,
  • Murali Monohar Pandey

DOI
https://doi.org/10.3390/pharmaceutics15030851
Journal volume & issue
Vol. 15, no. 3
p. 851

Abstract

Read online

Rotigotine (RTG) is a non-ergoline dopamine agonist and an approved drug for treating Parkinson’s disease. However, its clinical use is limited due to various problems, viz. poor oral bioavailability (max(brain)) compared to intranasal drug suspensions. Further, the intranasal RTG-LCNP significantly reduced the peak plasma drug concentration (Cmax(plasma)) compared to intranasal RTG suspensions. The direct drug transport percentage (DTP (%)) of optimized RTG-LCNP was found to be 97.3%, which shows effective direct nose-to-brain drug uptake and good targeting efficiency. In conclusion, RTG-LCNP enhanced drug brain availability, showing the potential for clinical application.

Keywords